Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Gilead helped develop remdesivir, an IV coronavirus treatment, with federal funding. Photo: Josh Edelson/AFP via Getty Images
Thirty-four state and territory attorneys general sent a letter today to federal health agencies asking the federal government to exercise march-in drug rights for remdesivir as a way "to help increase the supply of this drug and lower the price so it is accessible to our state residents."
The big picture: March-in rights — which would allow a patented drug developed with federal dollars to be licensed out to third parties — have never been exercised before. Gilead Sciences, the manufacturer and patent holder of remdesivir, did not immediately respond to requests for comment.